COVID 19: Drug Delivery Options to Succeed Sooner
Sponsored by: Aptar Pharma
- Covid 19
- Nasal Drugs
- Drug Delivery
Date: 26 January
Time: 9AM London/2.30PM Mumbai/5PM Beijing
Discovering injectable and nasal drug delivery treatments and vaccines
As the COVID-19 pandemic tightens its grip, it’s imperative to find effective treatment options and vaccines.
As the go-to expert in drug delivery, Aptar Pharma can leverage therapeutic insights, regulatory expertise and a wide portfolio of systems and services to accelerate and derisk our customer’s drug development process. In the end, we can help them transform ideas into new market opportunities that can improve and save patient lives.
In this webinar, we will review the options for therapeutic and vaccine treatment strategies using the nasal and injectable drug delivery routes. We will also discuss the rationale of drug delivery targets in the upper and lower airways and the selection of the appropriate device platform that drives formulation development.
We will also explore injectable options, highlight the key considerations for global vaccination programs, how to select the best packaging configuration for parenteral drug delivery and present Aptar Pharma’s coated elastomer offering.
Dr Julie Suman,
President, Next Breath, an Aptar Pharma company
Dr Suman holds a B.S. in Pharmacy and a Ph.D. in Pharmaceutical Sciences. She is a co-editor for Respiratory Drug Delivery Proceedings, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. She is a licensed Maryland pharmacist and has published her research in peer-reviewed journals, has presented during podium sessions at international meetings such as the FDA Visiting Professor Lecture Series, and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001.
Dr Jag Shur,
CEO, Nanopharm (an Aptar Pharma company), and Research Fellow at the University of Bath School of Pharmacy and Pharmacology
Dr Shur’s main area of research is investigation of the bioequivalence of orally inhaled and nasal drug products (OINDPs). The key theme of his research has been the development and application of novel tools to understand and quantify the microstructure of OINDPs.
Director Business Development, Injectables, Aptar Pharma
Ashraf Zaman is a Global Business Development Director at Aptar Pharma. He has been working in the Injectables market for the last 20 years. He is a Pharmacist and holds an MBA from London Business School.
VP Strategy, Business Development & Marketing, Aptar Pharma
Patrick Jeukenne is Vice-President of Strategy, Business Development and Marketing for Aptar Pharma. Patrick is an Industrial Pharmacist and graduated from the Universities of Liège (Belgium) and Montpellier (France). Patrick has held various roles (manufacturing, quality, sales, marketing and general management) since 1993 at multiple companies (GSK Vaccines, Amgen, Catalent, BD and Aptar) in the pharmaceutical and drug delivery world.
Key Learning Objectives
- Review treatment options for nasal and injectable drug delivery routes
- Understand formulation and device considerations for respiratory drug delivery
- Develop a strategy to accelerate lead injectable candidate selection for early clinical trials
- Research and Development
- Head of Quality
- Head Drug Delivery
- Analytical Chemists
- Head of Pharmaceutical Development
- Drug Formulation Development
- Manufacturing Scientist
- Clinical Manufacturing
- Science and Technology
- Head Outsourcing
- Scientific Business Development
- Business Development
- Laboratory Manager
- Packaging Development
- Regulatory Affairs
- Clinical Trial Consultants
- CMC Scientist
- Franchise Directors/Managers
- Brand Directors/Managers